Wendy L. Dixon - Jun 17, 2022 Form 4/A - Amendment Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Director
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Stock symbol
BDTX
Transactions as of
Jun 17, 2022
Transactions value $
$10,040
Form type
4/A - Amendment
Date filed
6/30/2022, 04:07 PM
Date Of Original Report
Jun 17, 2022
Previous filing
Jun 21, 2022
Next filing
Sep 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Award $10K +4.95K $2.03 4.95K Jun 17, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022.

Remarks:

On June 17, 2022 the Reporting Person filed a Form 4 (the "Original Form 4"), which inadvertently understated the number of shares of Common Stock issued to the Reporting Person by 886 shares. This amendment is being filed to correct the amounts listed in Columns 4 and 5 of Table I, and there have been no other changes to the information presented in the Original Form 4.